PRRS Patient Roles and Responsibilities Scale For cancer patients LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Patient Roles and Responsibilities Scale (PRRS) was developed to enable a broader evaluation of the impact of cancer and cancer treatment, measuring ‘real world’ roles and responsibilities such as caring for others and financial and employment responsibilities. Version 2, modified in 2024, removes two items from the Jobs and Careers Subscale. MEASURE NAME: Patient Roles and Responsibilities Scale (PRRS) VERSION: 2 NUMBER OF ITEMS: 16 to 23 PATIENT POPULATION: Cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Responsibilities and Social Life, Family Well-being, Financial Well-Being, Jobs and Careers TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template RELATED MEASURES: CRRS , FACT-G Caregiver , FACT-G7 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the PRRS can be obtained when licensing the measure. Users are not permitted to translate the PRRS without prior permission from FACIT.org. Permission may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor of the PRRS. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Shilling, V., Starkings, R., Jenkins, V. et al. Development and validation of the patient roles and responsibilities scale in cancer patients. Qual Life Res 27 , 2923–2934 (2018). https://doi.org/10.1007/s11136-018-1940-2. LICENSE THIS MEASURE Related Measures Related Measures CRRS Caregiver Roles and Responsibilities Scale LEARN MORE FACT-G Caregiver Functional Assessment of Cancer Therapy – General – Caregiver Version LEARN MORE FACT-G7 Functional Assessment of Cancer Therapy - General - 7 Item Version LEARN MORE

View all available languages for this measure. BACK FACT-HN Languages Afrikaans Arabic Bulgarian Chinese – Simplified Chinese – Traditional Croatian Czech Danish Dutch English Estonian Farsi Finnish French German Greek Gujarati Hebrew Hindi Hungarian Italian Japanese Kannada Korean Latvian Lithuanian Malay Malayalam Marathi Norwegian Polish Portuguese Romanian Russian Serbian Slovak Spanish Swedish Tagalog Tamil Telugu Thai Turkish Urdu Zulu

FACT-CSI and FACT-NET Functional Assessment of Cancer Therapy - Carcinoid Syndrome Symptom Index For patients with carcinoid syndrome LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FACT-CSI is a 24-item instrument for patients with carcinoid syndrome that can be scored as a single, multidimensional symptom index, or sub-scored by domain (disease-related physical symptoms, disease-related emotional symptoms, treatment side effects, and functional well-being), meeting FDA guidance recommendations while allowing maximum flexibility for both global and targeted symptom evaluation. Its development followed FDA guidelines for the patient-reported outcome measures, which emphasizes improvement in tumor-related symptoms or delays in symptom progression as evidence of clinical benefit for patients in oncology drug trials. Methods consistent with the FDA guidance were utilized along with prior experience developing 11 National Comprehensive Cancer Network (NCCN) symptom indexes to identify the highest priority symptoms and concerns of patients with GINET, PNET, and LNET, and of patients with CS, to inform the development of a set of NET symptom indexes appropriate for use in both clinical trial and clinic settings. MEASURE NAME: Functional Assessment of Cancer Therapy - Carcinoid Syndrome Symptom Index (FACT-CSI) / FACT-NET VERSION: 4 NUMBER OF ITEMS: FACT-CSI - 24 items FACT-GINET - 18 items FACT-GINET + CSI - 29 items FACT-LNET - 17 items FACT-LNET + CSI - 30 items FACT-PNET - 19 items FACT-PNET + CSI - 29 items PATIENT POPULATION: Patients 18 years and older with carcinoid syndrome, GINET, PNET or LNET RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: CSI, GINET, LNET, PNET TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. RELATED MEASURES: FACT-Ga , FACT-Hep , FACT-L DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-CSI can be obtained by registering for permission. Users are not permitted to translate the FACT-CSI without permission from FACIT.org. Permission from FACIT.org to translate the FACT-CSI may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Shaunfield S, Webster K, A, Kaiser K, Greene G, J, Yount S, E, Lacson L, Benson A, B, Halperin D, M, Yao J, C, Singh S, Feuilly M, Marteau F, Cella D: Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. Neuroendocrinology 2021;111:850-862. doi: 10.1159/000511482. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-Ga Functional Assessment of Cancer Therapy – Gastric LEARN MORE FACT-Hep Functional Assessment of Cancer Therapy – Hepatobiliary LEARN MORE FACT-L Functional Assessment of Cancer Therapy – Lung LEARN MORE

Download this measure in English. BACK CCSQ English Downloads Download PDF - Baseline Download DOC - Baseline Download PDF - On Therapy Download DOC - On Therapy

Download scoring documents for this measure. BACK FACT-Taxane Scoring Downloads Download DOC

Download scoring documents for this measure. BACK BESS Scoring Downloads Download PDF

DVT-LSI Deep Vein Thrombosis Leg Symptom Index For patients with deep vein thrombosis LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the DVT-LSI measure: MEASURE NAME: Deep Vein Thrombosis Leg Symptom Index (DVT-LSI) VERSION: 1 NUMBER OF ITEMS: 7 PATIENT POPULATION: Patients 18 and older with deep vein thrombosis RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Not available TIME FOR COMPLETION: 5 minutes SCORING: Included on measure RELATED MEASURES: FACT/GOG-NTX-4 , NVMBQ , FACT-G7 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the DVT-LSI can be obtained by registering for permission. Users are not permitted to translate the DVT-LSI without permission from FACIT.org. Permission from FACIT.org to translate the DVT-LSI may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Hudgens SA, Cella D, Caprini CA, Caprini JA. Deep vein thrombosis: validation of a patient-reported leg symptom index. Health Qual Life Outcomes . 2003 Dec 15;1:76. doi: 10.1186/1477-7525-1-76. PMID: 14675486; PMCID: PMC317368. LICENSE THIS MEASURE Related Measures Related Measures FACIT/GOG-NTX-4 Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity 4 Item Version LEARN MORE NVMBQ Nausea and Vomiting Management Barriers Questionnaire LEARN MORE FACT-G7 Functional Assessment of Cancer Therapy - General - 7 Item Version LEARN MORE

FACT-Cog Functional Assessment of Cancer Therapy - Cognitive Function For patients with Cognitive function issues LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACT-Cog measure: MEASURE NAME: Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) VERSION: 3 NUMBER OF ITEMS: 37 PATIENT POPULATION: Cancer patients 18 years and older with chemotherapy-induced cognitive problems RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Perceived Cognitive Impairments, Impact of Perceived Cognitive Impairments on QoL, Comments from Others, Perceived Cognitive Abilities TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and primary scores possible. RELATED MEASURES: FACIT-Fatigue , FACT-G , FACT-ES DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-Cog can be obtained by registering for permission. Users are not permitted to translate the FACT-Cog without permission from FACIT.org. Permission from FACIT.org to translate the FACT-Cog may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cheung, Y., Shwe, M., Chui, W., Chay, W., Ang, S., Dent, R., Yap, Y., Lo, S., Ng, R., & Chan, A. Effects of Chemotherapy and Psychosocial Distress on Perceived Cognitive Disturbances in Asian Breast Cancer Patients. The Annals of Pharmacotherapy 2012; 46: 1645-1655. doi: 10.1345/aph.1R408. Hajj A, Salameh P, Khoury R, Hachem R, Sacre H, Chahine G, Kattan J, Rabbaa Khabbaz L. Psychometric properties of the 37-item Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) scale. Future Oncol. 2022 Oct;18(33):3741-3753. doi: 10.2217/fon-2022-0438. Epub 2022 Nov 8. PMID: 36345984. Hajj A, Khoury R, Hachem R, Awad A, Hallit S, Sacre H, Nasr F, Karak FE, Chahine G, Kattan J, Khabbaz LR. Clinical and genetic factors associated with self-reported cognitive deficits in women with breast cancer: the "CAGE-Cog" study. BMC Cancer. 2022 Sep 19;22(1):996. doi: 10.1186/s12885-022-10077-6. PMID: 36123640; PMCID: PMC9487123. Jacobs, S., Jacobsen, P., Booth-Jones, am., Wagner, L., & Anasetti, C. Evaluation of the Functional Assessment of Cancer Therapy Cognitive Scale with Hematopoetic Stem Cell Transplant Patients. Journal of Pain and Symptom Management 2007; 33(1): 13-23. doi: 10.1016/j.jpainsymman.2006.06.011. Joly, F., Lange, M., Rigal, O., Correia, H., Giffard, B., Beaumont, J., Clisant, S., & Wagner, L. French version of the Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog) version 3. Support Care Cancer 2012; 20: 3297–3305. doi: 10.1007/s00520-012-1439-2. Oliveira, A.F., Santos, I.M., Fernandes, S. et al. Validation study of the Functional Assessment of Cancer Therapy-Cognitive Function-Version 3 for the Portuguese population. BMC Psychol 10, 305 (2022). https://doi.org/10.1186/s40359-022-01018-w. Park, J., Bae, S., Jung, Y. S., & Jung. Y. M. The psychometric properties of the Korean version of the functional assessment of cancer therapy-cognitive (FACT-Cog) in Korean patients with breast cancer. Support Care Cancer 2015; 23(9): 2695-2703. doi: 10.1007/s00520-015-2632-x. Vardy, J., Wong, K., Yi. Q., Park, A., Maruff, P., Wagner, L., & Tannock, I. Assessing cognitive function in cancer patients. Support Care Cancer 2006; 14: 1111–1118. doi: 10.1007/s00520-006-0037-6. Wagner, L., Sweet, J., Butt, Z., Lai, J.-S., & Cella, D. Measuring patient self-reported cognitive function: development of the functional assessment of cancer therapy–cognitive function instrument. Journal of Supportive Oncology 2009; 7(6): W32-W39. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-Fatigue Functional Assessment of Chronic Illness Therapy – Fatigue Scale LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE FACT-ES Functional Assessment of Cancer Therapy - Endocrine Symptoms LEARN MORE

View all available languages for this measure. BACK FACIT-Sp Languages Arabic Bengali Burmese Chinese - Traditional Chinese - Simplified Croatian Czech Danish Dutch English Farsi French German Greek Hebrew Hindi Hungarian Indonesian Italian Japanese Korean Lithuanian Malay Malayalam Marathi Nepali Norwegian Polish Portuguese Serbian Sinhala Spanish Slovak Slovene Swahili Swedish Tamil Telugu Thai Turkish Vietnamese

View all available languages for this measure. BACK FACT-MM Languages Arabic Chinese – Simplified Czech Dutch English French German Greek Italian Portuguese Spanish Thai

Our passion for linguistics is what drives us. FACITtrans Publications OUR PASSION FOR LINGUISTICS IS WHAT DRIVES US Below are selected publications and presentations by our staff, detailing the various approaches and challenges to attaining cross-cultural measurement equivalence. PublicationsTop Your search returned 0 results Japanese version of MICRA: introduction of the Shizuoka Cancer Center version Matsubayashi H, Harada R, Ishihara E, Kiyozumi Y, Higashigawa S, Suzuki R, Cella D, Bredle J, Savic L, Cella P Familial Cancer 25, 9 (2026) https://doi.org/10.1007/s10689-025-00524-1 Use of AI within COA linguistic validation and eCOA migration processes: analysis and good practice recommendations McKown, S., Arnold, B., Boucher, F., Correia H., Eremenco S., Geršić T., Johnson M., Koumbarou A., Matias I., Parks-Vernizzi E., Poepsel T., Son J., Strouse E., Terwee C.B., Wade M. Journal of Patient-Reported Outcomes 10, 34 (2026). https://doi.org/10.1186/s41687-026-01012-5 Cross-Cultural Adaptation and Psychometric Assessment of the Persian Version of the FACIT-Pal Quality of Life Instrument: A Study Protocol Mojahedi Mohammadi A., Mirshahi A., Cella P., Mahmoodi‐Bakhtiari B., Bakitas M., Bagcivan G., Sayyar A., Bredle J., Asgari A., Karbasi‐Motlagh M. Health Science Reports , 2026; 9:e72068 https://doi.org/10.1002/hsr2.72068 Ensuring relevance and equity in patient reported outcomes (PROs) in endometrial cancer: The SGO promote study (Patient Reported Outcomes Measurement Opportunities Through Equity) Wenzel L., McKinney C., Jensen S., Peipert D., Ganatra S., Bredle J., Sisodia R., Doll K., Philp L., Arend R., Dholakia J., Cella D. Gynecologic Oncology Volume 194, March 2025, pp. 137-144 https://doi.org/10.1016/j.ygyno.2025.02.020 Principles of good practice for concept definition in the context of translation and linguistic validation of clinical outcome assessments (COAs) Arnold, B., Weiss, D., Parks-Vernizzi, E. et al. J Patient Rep Outcomes 9 , 89 (2025). https://doi.org/10.1186/s41687-025-00920-2 Did The Kids Understand? Translating Key Concepts in Norwegian PROMIS Pediatric and Proxy Measures Boucher A., Parks-Vernizzi E., Cella P., Arnold B., Correia H., Sletten I., Garratt A. Presented at ISOQOL Milwaukee, October 2025. Principles of good practice for translation of electronic clinical outcome assessments Shalhoub, H., Turner, M., Bradley-Gilbride, A., Eremenco, S., Muehlan, H., Parks-Vernizzi, E., Arnold, B., Kulis, D., Anfray, C., Chaplin, J.E., Repo, J.P. J Patient Rep Outcomes 9, 26. https://doi.org/10.1186/s41687-025-00859-4 Translatability Assessment of the Fluid Overload from Nephrotic Syndrome Measure Pérez, B., Carlozzi, N., Arnold, B., Parks-Vernizzi, E., Herzberg, T., Peipert, J.D., Creguer, T., Hurt, C., Lai, J., Raghunathan, T., Ganatra, S., Hashemi, S., Scherr, B., Zhai, Y., Salmon, E. Quality of Life Research (2024) 33:S1–S235 Presented at ISOQOL Cologne, October 2024. Translation and linguistic validation of 24 PROMIS item banks into French Ahmed S, Parks-Vernizzi E, Perez B, Arnold B, Boucher A, Hossenbaccus M, Correia H, Bartlett SJ. Qual Life Res. 2024 Aug;33(8):2119-2127 . doi: 10.1007/s11136-024-03690-4. Epub 2024 Jun 12. PMID: 38865068; PMCID: PMC11286690. Dealing with the Complexities of Concurrently Translating and Implementing Electronic Clinical Outcome Assessments: Best Practices Roundtable: The Two-Step Dance of Concurrent Translation and Implementation of eCOAs Shalhoub, H., Turner, M., Bradley-Gilbride, A., Eremenco, S., Muhlan-Rehmer, H., Parks-Vernizzi, E., Arnold, B., Kulis, D., Anfray, C., Chaplin, J. Quality of Life Research (2024) 33:S1–S235 Presented at ISOQOL Cologne, October 2024. Prev 1 2 3 ... 12 1 ... 1 2 3 4 5 6 7 8 9 10 11 12 ... 12 Next We look forward to serving your study needs. Contact us to get started! FACITtrans is ISO 9001:2015 and ISO 17100:2015 certified.

FACT-Cx Functional Assessment of Cancer Therapy – Cervix For patients with cancer of the Cervix LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACT-Cx measure: MEASURE NAME: Functional Assessment of Cancer Therapy – Cervix (FACT-Cx) VERSION: 4 NUMBER OF ITEMS: 39 PATIENT POPULATION: Cervical cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Cervical Cancer Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACIT-CD , FACT-V , FACT-En DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-Cx can be obtained by registering for permission. Users are not permitted to translate the FACT-Cx without permission from FACIT.org. Permission from FACIT.org to translate the FACT-Cx may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Ashing-Giwa, K. Enhancing physical well-being and overall quality of life among underserved Latina-American cervical cancer survivors: feasibility study. Journal of Cancer Survivorship: Research and Practice 2008; 2(3):215-223. doi: 10.1007/s11764-008-0061-2. Chase, D., Huang, H., Wenzel, L., Cella, D., McQuellon, R., Long, H., Moore, D., & Monk, B. Quality of Life and survival in advanced cervical cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology 2012; 125(2): 315-319. doi: 10.1016/j.ygyno.2012.01.047. Long, H., Bundy, B., Grendys, E., Benda, J., McMeekin, D., Sorosky, J., Miller, D., Eaton, L. & Fiorica, J. Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study. Journal of Clinical Oncology 2005; 23(21): 4626-4633. doi: 10.1200/JCO.2005.10.021. Monk, B., Sill, M., McMeekin, D., Cohn, D., Ramondetta, L., Boardman, C., Benda, J., & Cella, D. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study. Journal of Clinical Oncology 2009; 27(28): 4649-4655. doi: 10.1200/JCO.2009.21.8909. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-CD Functional Assessment of Chronic Illness Therapy - Cervical Dysplasia LEARN MORE FACT-V Functional Assessment of Cancer Therapy – Vulva LEARN MORE FACT-En Functional Assessment of Cancer Therapy – Endometrial LEARN MORE